Serum high-sensitivity C-reactive protein and homocysteine changes during hormonal therapy in women with polycystic ovary syndrome: a prospective, matched study.
| Title | Serum high-sensitivity C-reactive protein and homocysteine changes during hormonal therapy in women with polycystic ovary syndrome: a prospective, matched study. |
| Publication Type | Journal Article |
| Year of Publication | 2010 |
| Authors | Makedos, A., Goulis D. G., Papanikolaou A., & Panidis D. |
| Journal | Angiology |
| Volume | 61 |
| Issue | 6 |
| Pagination | 595-601 |
| Date Published | 2010 Aug |
| ISSN | 1940-1574 |
| Keywords | Adolescent, Adult, Body Mass Index, C-Reactive Protein, Cyproterone Acetate, Desogestrel, Drug Therapy, Combination, Estrogens, Conjugated (USP), Ethinyl Estradiol, Female, Homocysteine, Humans, Linear Models, Phenotype, Polycystic Ovary Syndrome, Prospective Studies, Statistics, Nonparametric |
| Abstract | The study evaluated the effect of 5 hormonal regimes on serum levels of high-sensitivity C-reactive protein (hsCRP) and homocysteine (Hcy) in women with polycystic ovary syndrome (PCOS). Women with PCOS received (1) conjugated estrogens and cyproterone acetate (n = 22), (2) 17beta-estradiol and cyproterone acetate (n = 17), (3) ethinyl-estradiol and cyproterone acetate (high dose; n = 20), (4) ethinyl-estradiol plus cyproterone acetate (low dose; n = 12), or (5) ethinyl-estradiol plus desogetrel (n = 12). Both hsCRP and Hcy levels were measured at baseline and after 4, 7, and 12 months. The 17beta-estradiol/cyproterone acetate regime resulted in significant reduction of both hsCRP and Hcy levels (P < .001). The other 4 regimes only resulted in a reduction of Hcy levels (P < .001). In conclusion, the 17beta-estradiol/cyproterone acetate regime had the most favorable effects in women with PCOS regarding serum levels of hsCRP and Hcy. |
| DOI | 10.1177/0003319709361198 |
| Alternate Journal | Angiology |
| PubMed ID | 20395229 |
